Polyubiquitination of p53 by a ubiquitin ligase activity of p300

Science

Volumn 300, Issue 5617, 2003, Pages 342-344

  Grossman, Steven R ^a,b   Deato, Maria E ^a,d   Brignone, Chrystelle ^a,c   Chan, Ho Man ^a   Kung, Andrew L ^a,b   Tagami, Hideaki ^a   Nakatani, Yoshihiro ^a,b   Livingston, David M ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATALYST ACTIVITY; CELLS; DEGRADATION; TUMORS;

TUMOR SUPPRESSORS;

PROTEINS;

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; LIGASE; ONCOPROTEIN; ONCOPROTEIN E1A; POLYUBIQUITIN; PROTEASOME; PROTEIN MDM2; PROTEIN P300; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG;

BIOLOGY; CANCER; PROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN STABILITY; PROTEIN TARGETING; REGULATORY MECHANISM;

ADENOVIRUS E1A PROTEINS; ANIMALS; CATALYSIS; CELLS, CULTURED; E1A-ASSOCIATED P300 PROTEIN; EMBRYO; FIBROBLASTS; HUMANS; LIGASES; MICE; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; TRANS-ACTIVATORS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES; UBIQUITINS;

ANIMALIA;

EID: 0037432773     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1080386     Document Type: Article

References (25)

1. C. Prives, P. A. Haff, J. Pathol. 187, 112 (1999).
2. M. H. G. Kubbutat, S. N. Jones, K. H. Vousden, Nature 387, 299 (1997).
3. Y. Haupt, R. Maya, A. Kazaz, M. Oren, Nature 387, 296 (1997).
4. Z. Lai et al., J. Biol. Chem. 276, 31357 (2001).
5. M. S. Rodriguez, J. M. Desterro, S. Lain, D. P. Lane, R. T. Hay, Mol. Cell. Biol. 20, 8458 (2000).
6. C. M. Pickart, Trends Biochem. Sci. 25, 544 (2000).
7. C. G. Maki, J. M. Huibregtse, P. M. Howley, Cancer Res. 56, 2649 (1996).
8. M. Koegl et al., Cell 96, 635 (1999).
9. E. Querido, J. G. Teodoro, P. E. Branton, J. Virol. 71, 3526 (1997).
10. S. K. Chiou, E. White, J. Virol. 71, 3515 (1997).
11. Q. Zhu, J. Yao, G. Wani, M. A. Wani, A. A. Wani, J. Biol. Chem. 276, 29695 (2001).
12. S. R. Grossman, Eur. J. Biochem. 268, 2773 (2001).
13. S. R. Grossman et al., Mol. Cell 2, 405 (1998).
14. E3 enzymes catalyze the conjugation of Ub moieties by using isopeptide linkage to ε-amino groups on target protein lysines. Mono- or polyubiquitination may occur. E4 enzymes elongate shorter (<4 Ub moieties) Ub chains to form polyubiquitin conjugates on specific substrates.
15. Materials and methods are available as supporting material on Science Online.
16. Autoubiquitination reactions contain URC and a potential E3, without the addition of a specific substrate. Two potential products of such a reaction are ubiquitinated forms of the E3 and polymerized Ub, where Ub itself is the substrate.
17. K. L. Lorick et al., Proc. Natl. Acad. Sci. U.S.A. 96, 11364 (1999).
18. S. Hatakeyama, M. Yada, M. Matsumoto, N. Ishida, K. I. Nakayama, J. Biol. Chem. 276, 33111 (2001).
19. M. Hochstrasser, Nature Cell Biol. 2, E153 (2000).
20. R. Kurokawa et al., Science 279, 700 (1998).
21. S. R. Grossman et al., data not shown.
22. Q. Zhu, G. Wani, M. A. Wani, A. A. Wani, Cancer Res. 61, 64 (2001).
23. A. Ito et al., EMBO J. 21, 6236 (2002).
24. R. C. Conaway, C. S. Brower, J. W. Conaway, Science 296, 1254 (2002).
25. We thank E. Kieff, M. Ewen, and R. Drapkin for their critical reading of this manuscript; C. Prives for pS3-expressing baculovirus; G. Lozano for MDM2-null MEFs; and S. Sadis for helpful suggestions. This work was supported by a National Cancer Institute (NCI) Howard Temin Award (S.R.G.), an NCI grant CA15751 (D.M.L.), the Claudia Adams Barr Program (S.R.G. and A.L.K.), and the Harcourt General Charitable Foundation (S.R.G.).